TD Cowen Reiterates Buy Rating on GoodRx Holdings Inc. (GDRX)

TD Cowen analyst Charles Rhyee reiterated a Buy rating and $14.00 price target on GoodRx Holdings Inc. (NASDAQ: GDRX)

The analyst comments "We update our model following 1Q24 results, where mgmt. raised its 2024 guidance for revenue to $800-$810M (from ~$800M) and adj. EBITDA to >$250M (from ~$250M). We now est. 2024 rev of $813M and adj. EBITDA of $258M, an increase from $809M and $253M, which reflects continued growth in PTR revenue, in particular ramping ISP contribution, solid Pharma Man. Sol. growth and an improved 1Q24 gross margin profile (est. 2024 GM of 93.2% vs. prior est. of 92.0%). For 2025, we now estimate revenue of $930M and adj. EBITDA of $336M, which reflects continued growth across all businesses on top of a largely fixed OpEx structure."

For an analyst ratings summary and ratings history on GoodRx Holdings Inc. click here. For more ratings news on GoodRx Holdings Inc. click here.

Shares of GoodRx Holdings Inc. closed at $7.61 yesterday.

You May Also Be Interested In

• Norwegian Cruise (NCLH) PT Raised to $24 at TD Cowen
• Southwest (LUV) PT Raised to $61 at UBS Ahead of Q2 Print
• Darling Ingredients (DAR) PT Lowered to $70 at TD Cowen